SEDAR Interim Financial Statements

[
  {
    "companyName": "Biomark Diagnostics Inc.",
    "reportingPeriodEnd": "2025-12-31",
    "reportStatus": "Unaudited",
    "auditorName": null,
    "auditorKeyMatters": [],
    "balanceSheet": {
      "cashAndCashEquivalents": 487700,
      "shortTermInvestments": 798486,
      "accountsReceivable": 191688,
      "prepaidExpenses": 50372,
      "totalCurrentAssets": 1477874,
      "longTermInvestments": 3200,
      "propertyAndEquipmentNet": 16200,
      "rightOfUseAsset": 588137,
      "totalAssets": 2135783,
      "accountsPayableAndAccruedLiabilities": 224368,
      "clientDeposit": 8357,
      "currentPortionOfLeaseLiability": 318364,
      "dueToRelatedParties": 683246,
      "totalCurrentLiabilities": 1234335,
      "nonCurrentLeaseLiability": 393415,
      "totalLiabilities": 1627750,
      "shareCapital": 13781686,
      "contributedSurplus": 3777159,
      "deficit": -17050812,
      "totalEquity": 508033,
      "cashPerShare": 0.0046,
      "workingCapitalPerShare": 0.0023
    },
    "incomeStatement": {
      "revenue": 52779,
      "researchAndDevelopmentExpense": 471201,
      "depreciationOnRightOfUseAsset": 315844,
      "consultingFees": 265451,
      "professionalFees": 220575,
      "filingAndTransferAgentFees": 124568,
      "officeAndMiscellaneous": 74791,
      "shareBasedCompensation": 44804,
      "interestAndBankCharges": 38250,
      "travel": 16105,
      "depreciationOfPropertyAndEquipment": 12127,
      "totalOperatingExpenses": 1583716,
      "foreignExchangeLoss": 76095,
      "taxCreditIncome": -126227,
      "governmentGrants": -164219,
      "interestIncome": -38861,
      "totalOtherExpenses": -253212,
      "netLossComprehensiveLoss": -1277725,
      "basicAndDilutedLossPerShare": -0.02,
      "weightedAverageSharesOutstandingBasic": 105090213
    },
    "cashFlowStatement": {
      "netLossComprehensiveLoss": -1277725,
      "shareBasedCompensation": 44804,
      "depreciationPropertyEquipment": 12126,
      "depreciationRightOfUseAsset": 315844,
      "interestOnLeaseLiability": 25748,
      "changesInAccountsReceivable": -31026,
      "changesInPrepaidExpenses": -15767,
      "changesInAccountsPayableAndAccruedLiabilities": -43107,
      "cashUsedInOperatingActivities": -969103,
      "purchaseOfPropertyEquipment": -628140,
      "purchaseOfMarketableSecurities": -2883770,
      "proceedsFromDisposalOfMarketableSecurities": 2085284,
      "cashUsedInInvestingActivities": -1426626,
      "advancesFromRelatedParties": 267908,
      "repaymentOfDueToRelatedParties": -246000,
      "additionOfLeaseLiability": 646530,
      "repaymentOfLeaseLiability": -243331,
      "adjustmentsToLeaseLiability": -23444,
      "shareSubscriptionsReceived": 0,
      "cashFlowsFromFinancingActivities": 401663,
      "netDecreaseInCash": -1994066,
      "cashBeginningOfPeriod": 2481766,
      "cashEndOfPeriod": 487700
    },
    "investmentsAndOtherAssets": [
      {
        "type": "Investment in associate",
        "description": "Bio-Stream Diagnostics Inc. – license agreement and equity method investment",
        "ownershipPercentage": 18.64,
        "value": 3200,
        "notes": "Recorded at cost; CEO is director."
      },
      {
        "type": "Short-term investment (GICs)",
        "description": "Guaranteed Investment Certificates in CAD and USD",
        "ownershipPercentage": null,
        "value": 798486,
        "notes": "Includes GICs with maturities up to October 2026."
      }
    ],
    "shareStructure": {
      "authorizedShares": "Unlimited common shares, without par value",
      "issuedShares": 105090213,
      "classesOfShares": ["Common shares"],
      "warrants": [
        { "number": 7600000, "exercisePrice": 0.45, "expiryDate": "2026-12-29" },
        { "number": 5062000, "exercisePrice": 0.45, "expiryDate": "2026-05-04" },
        { "number": 4593984, "exercisePrice": 0.50, "expiryDate": "2028-03-31" },
        { "number": 9610000, "exercisePrice": 0.50, "expiryDate": "2028-03-26" }
      ],
      "options": [
        { "number": 4625000, "exercisePrice": 0.45, "expiryDate": "2027-04-18" }
      ],
      "rightsConvertibleInstruments": null
    },
    "managementCompensation": {
      "currency": "CAD",
      "periods": {
        "2025-04-01_to_2025-12-31": {
          "salaries": 0,
          "shareBased": 0,
          "consultingFees": 255150,
          "total": 255150
        },
        "2024-04-01_to_2024-12-31": {
          "salaries": 0,
          "shareBased": 0,
          "consultingFees": 255150,
          "total": 255150
        }
      },
      "namedIndividuals": [
        {
          "name": "CEO",
          "title": "Chief Executive Officer",
          "period": "2025-04-01_to_2025-12-31",
          "components": { "salary": 0, "bonus": 0, "total": 180000 },
          "notes": "Monthly consulting fee of $20,000; potential $250,000 bonus contingent on market capitalization not yet achieved."
        },
        {
          "name": "CFO",
          "title": "Chief Financial Officer (Interim)",
          "period": "2025-04-01_to_2025-12-31",
          "components": { "salary": 0, "bonus": 0, "total": 75150 },
          "notes": "Monthly consulting fee of $8,350."
        }
      ],
      "otherRelatedPartyTransactions": [
        {
          "counterparty": "BioMark Technologies Inc. (BTI)",
          "description": "Amount owed to parent company",
          "amount": 47798,
          "period": "2025-12-31"
        },
        {
          "counterparty": "CEO",
          "description": "Amount due to CEO",
          "amount": 499181,
          "period": "2025-12-31"
        },
        {
          "counterparty": "CFO",
          "description": "Amount due to CFO",
          "amount": 136268,
          "period": "2025-12-31"
        }
      ]
    },
    "subsequentEvents": []
  }
]